Jaguar Health (Jaguar Health) FCF Margin % : -323.96% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Jaguar Health FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Jaguar Health's Free Cash Flow for the three months ended in Dec. 2023 was $-7.45 Mil. Jaguar Health's Revenue for the three months ended in Dec. 2023 was $2.30 Mil. Therefore, Jaguar Health's FCF Margin % for the quarter that ended in Dec. 2023 was -323.96%.

As of today, Jaguar Health's current FCF Yield % is -44.55%.

The historical rank and industry rank for Jaguar Health's FCF Margin % or its related term are showing as below:

JAGX' s FCF Margin % Range Over the Past 10 Years
Min: -10223.94 Med: -354.23 Max: -162.87
Current: -340.56

During the past 11 years, the highest FCF Margin % of Jaguar Health was -162.87%. The lowest was -10223.94%. And the median was -354.23%.

JAGX's FCF Margin % is ranked worse than
61.49% of 1044 companies
in the Biotechnology industry
Industry Median: -146.375 vs JAGX: -340.56

Jaguar Health FCF Margin % Historical Data

The historical data trend for Jaguar Health's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jaguar Health FCF Margin % Chart

Jaguar Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-354.23

-162.87

-806.83

-290.89

-340.56

Jaguar Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-197.02	-504.31	-338.42	-241.38	-323.96

Competitive Comparison of Jaguar Health's FCF Margin %

For the Biotechnology subindustry, Jaguar Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jaguar Health's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Jaguar Health's FCF Margin % falls into.

Jaguar Health FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Jaguar Health's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-33.242	/	9.761
	=	-340.56 %

Jaguar Health's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.451	/	2.3
	=	-323.96 %

Jaguar Health FCF Margin % Related Terms

Thank you for viewing the detailed overview of Jaguar Health's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jaguar Health (Jaguar Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (NAS:JAGX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

1JAA:Germany

Address

200 Pine Street, Suite 400, San Francisco, CA, USA, 94104

Website

http://www.jaguar.health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Executives

Anula Jayasuriya	director	5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Pravin R Chaturvedi	officer: Chief Scientific Officer	C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104
Lisa A Conte	director, officer: CEO & President	213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carol R. Lizak	officer: Chief Accounting Officer	201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
James J Bochnowski	director	C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402
Jonathan S. Wolin	officer: Chief of Staff, CCO & GC	201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Jonathan B. Siegel	director	C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019
Bryan Ezralow 1994 Trust Dated December 22, 1994	10 percent owner	23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302
Bryan Ezralow	10 percent owner	THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549
Nantucket Investments Ltd	10 percent owner	PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH
Jonathan M Glaser	10 percent owner	11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025
Murray David Macnaughtan	director	C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Greg J Divis	director	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jeffery C. Johnson	director	C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901
Sagard Capital Partners, L.p.	10 percent owner	280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017